Short-term outcomes from the 'Watch and Wait' (WoW) study : prospective cohort study
(2025) In BJS Open 9(1). p.1-6- Abstract
BACKGROUND: Despite absence of level 1 evidence on the long-term oncological safety of non-operative management for rectal cancer (watch and wait), increased implementation has occurred globally over the past decades. In Sweden, a pan-national prospective non-randomized study was initiated in 2017 to assess its implementation.
METHOD: Patients with biopsy-proven rectal cancer receiving neoadjuvant therapy according to national guidelines in whom a clinical complete response was detected at reassessment were eligible for inclusion following informed consent. Only patients with an opportunistic watch-and-wait approach were included. Inclusion and follow-up, according to the study protocol, was managed at the participating study... (More)
BACKGROUND: Despite absence of level 1 evidence on the long-term oncological safety of non-operative management for rectal cancer (watch and wait), increased implementation has occurred globally over the past decades. In Sweden, a pan-national prospective non-randomized study was initiated in 2017 to assess its implementation.
METHOD: Patients with biopsy-proven rectal cancer receiving neoadjuvant therapy according to national guidelines in whom a clinical complete response was detected at reassessment were eligible for inclusion following informed consent. Only patients with an opportunistic watch-and-wait approach were included. Inclusion and follow-up, according to the study protocol, was managed at the participating study centres. The primary outcome measure of the study is 3-year disease-free survival. Here, the secondary short-term outcomes local regrowth rate, distant metastasis rate and outcomes after surgery for regrowth, at 6 months follow-up, are reported.
RESULTS: Between January 2017 and February 2023, 211 patients with a clinical complete response were included in the study. Thirty-three (16%) patients developed suspicious regrowth within 6 months of inclusion. Thirty-two of 33 patients had abdominal resectional surgery for regrowth. The curative intention rate was 94% for patients with regrowth. Three patients (1.4%) developed distant metastases within 6 months of inclusion.
CONCLUSION: This Swedish national study on watch and wait reports regrowth rates after 6 months are in line with previous reports in the literature. Nearly all patients with early regrowth could be treated with salvage surgery and curative intent.
(Less)
- author
- organization
- publishing date
- 2025-02
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Humans, Prospective Studies, Male, Female, Rectal Neoplasms/therapy, Watchful Waiting, Aged, Sweden, Middle Aged, Neoadjuvant Therapy, Disease-Free Survival, Neoplasm Recurrence, Local, Adult, Aged, 80 and over, Treatment Outcome
- in
- BJS Open
- volume
- 9
- issue
- 1
- article number
- zrae151
- pages
- 1 - 6
- publisher
- Wiley
- external identifiers
-
- scopus:85216305571
- pmid:39851200
- ISSN
- 2474-9842
- DOI
- 10.1093/bjsopen/zrae151
- language
- English
- LU publication?
- yes
- additional info
- © The Author(s) 2025. Published by Oxford University Press on behalf of BJS Foundation Ltd.
- id
- afa54c8e-f1c5-47d5-a8a0-b3bfeb96699d
- date added to LUP
- 2025-02-02 21:06:02
- date last changed
- 2025-07-12 15:41:20
@article{afa54c8e-f1c5-47d5-a8a0-b3bfeb96699d, abstract = {{<p>BACKGROUND: Despite absence of level 1 evidence on the long-term oncological safety of non-operative management for rectal cancer (watch and wait), increased implementation has occurred globally over the past decades. In Sweden, a pan-national prospective non-randomized study was initiated in 2017 to assess its implementation.</p><p>METHOD: Patients with biopsy-proven rectal cancer receiving neoadjuvant therapy according to national guidelines in whom a clinical complete response was detected at reassessment were eligible for inclusion following informed consent. Only patients with an opportunistic watch-and-wait approach were included. Inclusion and follow-up, according to the study protocol, was managed at the participating study centres. The primary outcome measure of the study is 3-year disease-free survival. Here, the secondary short-term outcomes local regrowth rate, distant metastasis rate and outcomes after surgery for regrowth, at 6 months follow-up, are reported.</p><p>RESULTS: Between January 2017 and February 2023, 211 patients with a clinical complete response were included in the study. Thirty-three (16%) patients developed suspicious regrowth within 6 months of inclusion. Thirty-two of 33 patients had abdominal resectional surgery for regrowth. The curative intention rate was 94% for patients with regrowth. Three patients (1.4%) developed distant metastases within 6 months of inclusion.</p><p>CONCLUSION: This Swedish national study on watch and wait reports regrowth rates after 6 months are in line with previous reports in the literature. Nearly all patients with early regrowth could be treated with salvage surgery and curative intent.</p>}}, author = {{Rydbeck, Daniel and Azhar, Najia and Blomqvist, Lennart and Chabok, Abbas and Folkesson, Joakim and Gerdin, Anders and Hermus, Linda and Matthiessen, Peter and Martling, Anna and Nilsson, Per J and Angenete, Eva}}, issn = {{2474-9842}}, keywords = {{Humans; Prospective Studies; Male; Female; Rectal Neoplasms/therapy; Watchful Waiting; Aged; Sweden; Middle Aged; Neoadjuvant Therapy; Disease-Free Survival; Neoplasm Recurrence, Local; Adult; Aged, 80 and over; Treatment Outcome}}, language = {{eng}}, number = {{1}}, pages = {{1--6}}, publisher = {{Wiley}}, series = {{BJS Open}}, title = {{Short-term outcomes from the 'Watch and Wait' (WoW) study : prospective cohort study}}, url = {{http://dx.doi.org/10.1093/bjsopen/zrae151}}, doi = {{10.1093/bjsopen/zrae151}}, volume = {{9}}, year = {{2025}}, }